Hoth Therapeutics, Inc. (HOTH) News
Filter HOTH News Items
HOTH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HOTH News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest HOTH News From Around the Web
Below are the latest news stories about HOTH THERAPEUTICS INC that investors may wish to consider to help them evaluate HOTH as an investment opportunity.
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & MoreNMRA and HOTH are in the spotlight in the biotech sector on study data announcement. |
Hoth Therapeutics Responds to Market Rumors and Shareholder InquiriesHoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative, patient-focused treatments, today responded to recent market rumors and inquiries from shareholders regarding its financial plans and ongoing clinical trials. |
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets GoalHoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients. |
Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment SuccessPhase 2a Trial Shows 100% Success in Mitigating Skin Toxicity from Cancer Therapy |
Top Midday GainersHoth Therapeutics (HOTH) said Tuesday that interim results from a phase 2a trial of HT-001 showed th |
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin ToxicitiesHoth Therapeutics, Inc. (NASDAQ: HOTH), a leading biopharmaceutical company focused on patient-centric solutions, today shared encouraging interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients. |
Top Midday DeclinersHoth Therapeutics (HOTH) is working to commercialize a potential obesity therapy co-developed by the |
Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity TreatmentHoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA). This agreement provides Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University. |
MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000A trio of tiny biotech firms have announced plans to invest up to $1 million in Bitcoin. They are not the next MicroStrategy. |
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment StudyHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology. This study was performed and too |